TUCSON, Ariz.--(BUSINESS WIRE)--Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development, announced the formation of its tenth consortium: The Duchenne Regulatory Sciences Consortium (D-RSC). In partnership with Parent Project Muscular Dystrophy (PPMD), which has committed nearly one million dollars, the D-RSC will apply C-Path’s proven consensus science model to the battle against Duchenne. Founding members of the D-RSC include Santhera Pharmaceuticals, PTC Therapeutics and Dr. Brenda Wong from Cincinnati Children’s Hospital Medical Center. C-Path and Sarepta Therapeutics, Inc. are currently working together to reach a final agreement for Sarepta to join the D-RSC consortium. Several additional consortium members will be added soon.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
